PhRMA Statement on FDA Authorizing Florida’s Importation Plan

WASHINGTON, D.C. (January 5, 2024) – Today, Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl released the following statement in response to the U.S. Food and Drug Administration authorizing Florida’s Agency for Health Care Administration’s drug importation program:

“We are deeply concerned with the FDA’s reckless decision to approve Florida’s state importation plan. Ensuring patients have access to needed medicines is critical, but the importation of unapproved medicines, whether from Canada or elsewhere in the world, poses a serious danger to public health. Politicians need to stop getting between Americans and their health care. PhRMA is considering all options for preventing this policy from harming patients.”

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $800 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.MAT.org
www.Facebook.com/PhRMA
www.X.com/PhRMA